NCT05813626View on ClinicalTrials.gov

Neoadjuvant Chemotherapy Plus Toripalimab in Patients With Locoregionally Advanced Nasopharyngeal Carcinoma

PHASE2RecruitingINTERVENTIONAL

Enrollment

89

Participants

Timeline

Start Date

April 3, 2023

Primary Completion Date

October 30, 2024

Study Completion Date

October 30, 2027

Conditions

Nasopharyngeal Carcinoma

Interventions

DRUG

Toripalimab

Toripalimab (240 mg Q3W for 3 cycles) combine with chemotherapy

Trial Locations (1)

310022

RECRUITING

Zhejiang Cancer Hospital, Hangzhou

All Listed Sponsors

lead

Zhejiang Cancer Hospital

OTHER